Evidence map›Paper›PMID 33188281›Full record

ArticleCell death and differentiation2021

Fra-2/AP-1 regulates melanoma cell metastasis by downregulating Fam212b.

Guang-Liang Chen, Rui Li, Xiao-Xiang Chen, Juan Wang, Shan Cao, Rui Song, Ming-Chun Zhao, Li-Ming Li, Nicole Hannemmann, Georg Schett and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell death and differentiation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Role of Fra-2 in cancer.Cell death and differentiation · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Guang-Liang Chen *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Rui Li *Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Germany.
Xiao-Xiang Chen *Department of Rheumatology, Renji Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Juan WangDepartment of Rheumatology, Renji Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Shan CaoDepartment of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Germany.
Rui SongDepartment of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Germany.
Ming-Chun ZhaoDepartment of Pathology, Guilin People's Hospital, Guilin, Guangxi, China.
Li-Ming LiDepartment of Pediatric Surgery, Guigang People's Hospital, Guigang, Guangxi, China.
Nicole HannemmannDepartment of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Germany.
Georg SchettDepartment of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Germany.ORCID http://orcid.org/0000-0001-8740-9615
Cheng QianDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Aline BozecDepartment of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Germany. aline.bozec@uk-erlangen.de.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEShanghai Jiao Tong University · CNGuigang City People's Hospital · CNGuilin Medical University · CNShanghai Medical College of Fudan University · CNSun Yat-sen University · CN

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) A01-CRC1811Deutsche Forschungsgemeinschaft (German Research Foundation) B03811/1-6Deutsche Forschungsgemeinschaft (German Research Foundation) B03811/1-7
6 · The paper itself

Abstract

Metastatic melanoma remains a challenging disease. Understanding the molecular mechanisms how melanoma becomes metastatic is therefore of interest. Herein we show that downregulation of the AP-1 transcription factor member Fra-2 in melanoma cells is associated with an aggressive melanoma phenotype in vitro and in vivo. In vitro, Fra-2 knockdown in melanoma cells promoted cell migration and invasion associated with increased Snail-1, Twist-1/2, and matrix metalloproteinase-2 (MMP-2) expression. In vivo, Fra-2 knockdown in a melanoma cell line led to increased metastasis into the lungs and liver. The increased metastatic potential of Fra-2 knockdown melanoma cells was likely due to an accelerated cell cycle transition and increased tissue angiogenesis. Using Fra-2 knockdown cell lines microarray analysis, we identified the protein Fam212b (family with sequence similarity 212 member B) as a downstream target of Fra-2. By additional knockdown of Fam212b in Fra-2 mutant cells, we mitigated the cell migration, invasion, and cell cycle transition phenotype induced by Fra-2 knockdown. Furthermore, Fam212b overexpression enhanced β-catenin pathway. Finally, Fam212b expression is correlated with increased melanoma metastasis and poor clinical outcomes in human patients. In summary, these findings reveal the Fra-2-Fam212b axis as a new pathway of melanoma metastasis, which can be in the future used as potential marker of the metastatic properties of melanoma.

Indexed as

Animalsbeta CateninCell Line, TumorCell MovementDown-RegulationFos-Related Antigen-2HumansIntracellular Signaling Peptides and ProteinsMaleMatrix Metalloproteinase 2MelanomaMiceMice, Inbred BALB CMice, Inbred C57BLMice, NudeNeoplasm Invasivenessbeta CateninFOSL2 protein, humanFOS protein, humanFos-Related Antigen-2INKA1 protein, humanIntracellular Signaling Peptides and ProteinsMatrix Metalloproteinase 2Proto-Oncogene Proteins c-fosTranscription Factor AP-1

Identifiers

PMID33188281
PMCPMC8027635
OpenAlexW3098621528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.